BIOCON: CO HAS APPROVED ISSUANCE OF COMMERCIAL PAPERS UP TO AN AMOUNT NOT EXCEEDING RS. 600 CRORES IN ONE OR MORE TRANCHES ON PRIVATE PLACEMENT BASIS

 04 Apr 2025 09:26 PM

BIOCON: CO HAS APPROVED ISSUANCE OF COMMERCIAL PAPERS UP TO AN AMOUNT NOT EXCEEDING RS. 600 CRORES IN ONE OR MORE TRANCHES ON PRIVATE PLACEMENT BASIS

BIOCON: CO TO CONSIDER Q4 RESULT ON APRIL 30

 02 Apr 2025 05:59 PM

BIOCON: CO TO CONSIDER Q4 RESULT ON APRIL 30

BIOCON: BOARD MEETING ON APRIL 4 TO CONSIDER AND APPROVE THE RAISING OF FUNDS THROUGH ISSUANCE OF COMMERCIAL PAPERS (CPS) OR THROUGH ANY OTHER MODE ON PRIVATE PLACEMENT BASIS

 01 Apr 2025 09:03 PM

BIOCON: BOARD MEETING ON APRIL 4 TO CONSIDER AND APPROVE THE RAISING OF FUNDS THROUGH ISSUANCE OF COMMERCIAL PAPERS (CPS) OR THROUGH ANY OTHER MODE ON PRIVATE PLACEMENT BASIS

BIOCON: CO UNIT HAS RECEIVED APPROVAL FROM U.S. FDA FOR ITS ANDA NOREPINEPHRINE BITARTRATE INJECTION USP, SINGLE-DOSE VIAL, NOREPINEPHRINE BITARTRATE INJECTION IS INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSION

 24 Mar 2025 08:56 AM

BIOCON: CO UNIT HAS RECEIVED APPROVAL FROM U.S. FDA FOR ITS ANDA NOREPINEPHRINE BITARTRATE INJECTION USP, SINGLE-DOSE VIAL, NOREPINEPHRINE BITARTRATE INJECTION IS INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSION

Biocon shares in focus after successful results of Yesintek in Phase 3

 10 Mar 2025 09:15 AM

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six months, it has decreased by 10.84%, while the stock fell by 12.23% over the past three months. In the last month, the price has declined by 13.70%.

BIOCON: CO UNIT BIOCON BIOLOGICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF YESINTEK™ BIOSIMILAR TO USTEKINUMAB FOR CHRONIC PLAQUE PSORIASIS || YESINTEK DEMONSTRATES EQUIVALENT EFFICACY AND SAFETY TO STELARA

 07 Mar 2025 06:54 PM

BIOCON: CO UNIT BIOCON BIOLOGICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF YESINTEK™ BIOSIMILAR TO USTEKINUMAB FOR CHRONIC PLAQUE PSORIASIS || YESINTEK DEMONSTRATES EQUIVALENT EFFICACY AND SAFETY TO STELARA

Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the US

 07 Mar 2025 09:55 AM

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insulin, while Civica will manufacture and commercialize it, enhancing patient access to high-quality, affordable medication for diabetes management.

BIOCON: CO UNIT BIOCON BIOLOGICS AND CIVICA, INC. COLLABORATE TO EXPAND INSULIN ASPART ACCESS IN THE UNITED STATES

 06 Mar 2025 05:51 PM

BIOCON: CO UNIT BIOCON BIOLOGICS AND CIVICA, INC. COLLABORATE TO EXPAND INSULIN ASPART ACCESS IN THE UNITED STATES

Stocks to buy today: Biocon, PFC among top 9 trading ideas for 5 March 2025

 05 Mar 2025 09:25 AM

Indian market to trade higher on Wednesday, influenced by positive global trends. Nifty formed a bullish candle but showed lower lows in the last four sessions, indicating shifting resistance. Experts recommend specific stock buys with designated target prices and stop losses for short-term trading.

Biocon shares up 3% after US FDA nod for key cancer drugs

 05 Mar 2025 09:15 AM

Biocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, enhancing its US oncology market presence. The company also got tentative approval for Rivaroxaban. Despite recent stock declines, analysts suggest a potential 22% upside. Biocon's Q3 profits dropped sharply due to a previous one-time gain.